Renowned Faculty Join Medlive Advisory Board
Medical Experts Provide Guidance for Educational Design BOSTON, July 16, 2024 – PlatformQ Health is excited to announce the formation of the Medlive Advisory Board led by key opinion leaders Read More
Outcomes Data Reveals Knowledge Gaps Among Those Treating Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) remains difficult to treat, and disproportionately affects women of color. To address these challenges, PlatformQ Health joined together with TOUCH: The Black Breast Cancer Alliance and the National Breast Cancer Foundation to develop a tethered educational program to empower patients in treatment decision making and to help facilitate better patient-clinical communication through sharing of real-world outcomes. Read More
PlatformQ Health Launches Medlive – An Integrated Education and Engagement Model
New platform to empower patients, caregivers, physicians, and healthcare partners BOSTON, May 28, 2024 – PlatformQ Health is pleased to announce Medlive, a new platform that embodies the company’s mission Read More
Continuing Medication Education Enhances Clinicians’ Knowledge of Homozygous Familial Hypercholesterolemia
Early treatment of homozygous familial hypercholesterolemia (HoFH) improves outcomes for children and reduces the risk of progressive atherosclerotic cardiovascular disease. Unfortunately, the disease often goes undetected until it is in the advanced stages. Read More
What Medical Education Reveals about Barriers to Adoption of Biologic Agents for Moderate-to-Severe Asthma
For people with moderate-to-severe asthma, personalization of biologic agents is warranted based on factors such as biomarkers and comorbidities. PlatformQ Health and the Asthma and Allergy Foundation of America (AAFA) conducted a CME-certified, case based, expert panel discussion that featured a live Q&A session with leading faculty from the Asthma Center at Cincinnati Children's Hospital Medical Center and the Division of Allergy and Immunology at Northwestern University's Feinberg School of Medicine, as well as AAFA's public health manager. Read More
Lessons Learned by Tracking Educational Program Outcomes
PlatformQ Health is known for its outcomes-driven education. At this year’s European Conference on Rare Diseases, we co-presented two posters highlighting outcomes and lessons learned from recent programming. Read More
Understanding the Impact of CME on Participant Knowledge and Behavior
The first FDA-approved gene therapy for pediatric patients with Duchenne muscular dystrophy (DMD) is now available. This is a genetic disorder that presents as progressive muscle degeneration and weakness. Read More
Partnership Pulse
As we look forward to the holiday season, we are filled with gratitude to all our incredible partners. Read More
Program Outcomes Demonstrate Dire Need for FOP Education
PlatformQ Health, the National Organization for Rare Disorders (NORD), the International Fibrodyslpasia Ossificans Progressiva Association (IFOPA) Read More
Health Equity Drives Extension of Exclusive Alliance Between PlatformQ Health and the Asthma and Allergy Foundation of America
The Asthma and Allergy Foundation of America (AAFA) and PlatformQ Health have extended their long-standing collaboration for another three years to continue bringing trusted digital education to those affected by asthma and related conditions. Read More
Fall 2023 Partnership Pulse
As we look forward to the holiday season, we are filled with gratitude to all our incredible partners. Read More
Uncovered Barriers to Clinical Trial Enrollment Among Patients with Non-Hodgkin’s Lymphoma
Clinical trials are crucial for advancing care for non-Hodgkin's lymphoma (NHL), however, accrual in these studies remains low. To address this issue, PlatformQ Health, the Leukemia & Lymphoma Society, BlackDoctor.org, and Partners for Advancing Clinical Education co-produced the BUILD-NHL Trial Equity Initiative. Read More
